Join Growin Stock Community!

Cytek biosciences, inc.CTKB.US Overview

US StockHealthcare
(No presentation for CTKB)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CTKB AI Insights

CTKB Overall Performance

CTKB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CTKB Recent Performance

-3.04%

Cytek biosciences, inc.

0.05%

Avg of Sector

-0.31%

S&P500

CTKB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CTKB Key Information

CTKB Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CTKB Profile

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Price of CTKB

CTKB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CTKB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.52
PE Ratio (TTM)
-
Forward PE
61.06
PS Ratio (TTM)
2.84
PB Ratio
1.52
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
51.84%
Net Margin
-33.02%
Revenue Growth (YoY)
0.52%
Profit Growth (YoY)
-5.98%
3-Year Revenue Growth
8.73%
3-Year Profit Growth
3.84%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.52
PE Ratio (TTM)
-
Forward PE
61.06
PS Ratio (TTM)
2.84
PB Ratio
1.52
Price-to-FCF
-
Gross Margin
51.84%
Net Margin
-33.02%
Revenue Growth (YoY)
0.52%
Profit Growth (YoY)
-5.98%
3-Year Revenue Growth
8.73%
3-Year Profit Growth
3.84%

  • When is CTKB's latest earnings report released?

    The most recent financial report for Cytek biosciences, inc. (CTKB) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CTKB's short-term business performance and financial health. For the latest updates on CTKB's earnings releases, visit this page regularly.

  • What is the operating profit of CTKB?

    According to the latest financial report, Cytek biosciences, inc. (CTKB) reported an Operating Profit of -5.59M with an Operating Margin of -9% this period, representing a decline of 287.34% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is CTKB's revenue growth?

    In the latest financial report, Cytek biosciences, inc. (CTKB) announced revenue of 62.14M, with a Year-Over-Year growth rate of 8.12%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does CTKB have?

    At the end of the period, Cytek biosciences, inc. (CTKB) held Total Cash and Cash Equivalents of 90.85M, accounting for 0.2 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does CTKB go with three margins increasing?

    In the latest report, Cytek biosciences, inc. (CTKB) did not achieve the “three margins increasing” benchmark, with a gross margin of 52.9%%, operating margin of -9%%, and net margin of -70.9%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CTKB's profit trajectory and future growth potential.

  • Is CTKB's EPS continuing to grow?

    According to the past four quarterly reports, Cytek biosciences, inc. (CTKB)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.34. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CTKB?

    Cytek biosciences, inc. (CTKB)'s Free Cash Flow (FCF) for the period is -1.68M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 254.4% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CTKB?

    The latest valuation data shows Cytek biosciences, inc. (CTKB) has a Price-To-Earnings (PE) ratio of -8.5 and a Price/Earnings-To-Growth (PEG) ratio of -0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.